122 related articles for article (PubMed ID: 24621673)
1. N-acetylcysteine in COPD may be beneficial, but for whom?
Cazzola M; Matera MG
Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
[No Abstract] [Full Text] [Related]
2. N-acetylcysteine for COPD: the evidence remains inconclusive.
Turner RD; Bothamley GH
Lancet Respir Med; 2014 Apr; 2(4):e3. PubMed ID: 24717631
[No Abstract] [Full Text] [Related]
3. N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply.
Zheng JP; Zhong NS
Lancet Respir Med; 2014 Apr; 2(4):e3-4. PubMed ID: 24717632
[No Abstract] [Full Text] [Related]
4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
5. N-acetylcysteine for chronic obstructive pulmonary disease?
Lavietes MH
Respiration; 1999; 66(6):491-2. PubMed ID: 10847827
[No Abstract] [Full Text] [Related]
6. [Acetylcysteine in the treatment of severe COPD].
Dekhuijzen PN
Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1222-6. PubMed ID: 16796172
[TBL] [Abstract][Full Text] [Related]
7. Genetics affect IPF treatment response to N-acetylcysteine.
Lozano-Wilhelmi M
Lancet Respir Med; 2015 Oct; 3(10):752. PubMed ID: 26388174
[No Abstract] [Full Text] [Related]
8. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
9. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
10. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
11. [Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression].
Entzian P
Pneumologie; 1998 Jul; 52(7):396-7. PubMed ID: 9738391
[No Abstract] [Full Text] [Related]
12. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
13. Topical N-acetylcysteine in ichthyosis: Experience in 18 patients.
Kaplan L; Castelo-Soccio L
Pediatr Dermatol; 2018 Jul; 35(4):528-530. PubMed ID: 29582451
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcysteine somewhere between Scylla and Charybdis.
Sochman J
J Am Coll Cardiol; 2010 Sep; 56(13):1067; author reply 1067-8. PubMed ID: 20846610
[No Abstract] [Full Text] [Related]
15. IV versus oral N-acetylcysteine.
Gupta AK; Su MK; Greller HA; Lee DC; Chan GM
Ann Emerg Med; 2009 Dec; 54(6):857-8; author reply 858-9. PubMed ID: 19942075
[No Abstract] [Full Text] [Related]
16. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease.
Gerrits CM; Herings RM; Leufkens HG; Lammers JW
Eur Respir J; 2003 May; 21(5):795-8. PubMed ID: 12765423
[TBL] [Abstract][Full Text] [Related]
18. N-Acetylcysteine for the prevention of renal dysfunction in high-risk patients undergoing coronary bypass graft surgery: an unfulfilled promise?
Filep JG
Crit Care Med; 2007 May; 35(5):1431-3. PubMed ID: 17446744
[No Abstract] [Full Text] [Related]
19. N-acetylcysteine is unlikely to reduce hospitalisation for chronic obstructive pulmonary disease.
Ernst P; Suissa S
Eur Respir J; 2003 Nov; 22(5):865; author reply 865-6. PubMed ID: 14621098
[No Abstract] [Full Text] [Related]
20. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency.
Atkuri KR; Mantovani JJ; Herzenberg LA; Herzenberg LA
Curr Opin Pharmacol; 2007 Aug; 7(4):355-9. PubMed ID: 17602868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
